n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, March 14th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Digipath, Inc. (DIGP)

The Wall Street Transcript, CFN Media Group, Promotion Stock Secrets, Cannabis Financial Network News, SmallCapVoice, SECFilings News, Otcstockexchange, Whisper from Wall Street, SmallCapStockPlays, Wallstreetbuzz, DSR News, Investor News Source, StockRockandRoll, PennyStockLocks, TheMicrocapNews, AddictivePennyStocks, PricelessPennyStocks, PennyStockRumors.net, and Real Pennies reported on Digipath, Inc. (DIGP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Digipath, Inc. is an independent cannabis testing and media organization. The Company supports the cannabis industry’s best practices for reliable testing, education, and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath has its headquarters in Las Vegas, Nevada.

Digipath’s two business units are Digipath Labs and TNM News Corp. The National Marijuana News (TNMNews) is its unbiased cannabis news site and talk radio show. It focuses on the political, economic, medicinal, and cultural dimensions of the medicinal and recreational marijuana industry. Digipath Labs is the cannabis testing subsidiary of the Company.
  
Digipath Labs is working to set the industry standard for testing all kinds of cannabis-based products using Food and Drug Administration (FDA)-compliant laboratory equipment and proprietary Standard Operating Procedures (SOP) to ensure product safety and efficacy. Its flagship cannabis analytical testing laboratory in Las Vegas, Nevada, helps safeguard patient safety and provide cannabinoid and terpenoid potency data, which can be used to match specific products to medical conditions.

Digipath's accomplishments in 2015 included opening its first state-of-the-art cannabis testing lab, Digipath Labs, in Las Vegas, Nevada, and testing 250 cannabis flower samples, representing over 1,250 pounds of cured flower from a number of the 16 licensed growers.

Digipath Labs announced in July of 2016 that it signed a laboratory testing agreement with The Cannavative Group. Digipath Labs will test all cannabis products grown and produced by The Cannavative Group for potency, terpenoids, moisture content, foreign matter, heavy metals, microbials, mycotoxins, and pesticide residue. The Cannavative Group is a fully licensed medical cannabis cultivator and producer located in Washoe County, Nevada.

Digipath Labs has been chosen as the laboratory testing service provider for The Clinic Nevada, LLC. The Clinic has numerous retail and cultivation locations in Colorado and Illinois. The Clinic Nevada is a licensed cannabis cultivator, producer, and dispenser located in Las Vegas, Nevada. Currently, Digipath tests products coming out of The Clinic Nevada's production facility branded as "The Lab".

Recently, Digipath announced that it entered into an agreement with a strategic investor, OC Testing LLC, to build additional cannabis testing labs. Mr. Todd Denkin, Digipath COO, said, "This agreement is an important step in expanding the Digipath Labs brand in the cannabis lab testing market and provides us with a strategic and financial partner as we scale into other legal cannabis markets.”

At the end of February, Digipath announced that it appointed Alfredo Axtmayer, M.D. to its Board of Directors. Dr. Axtmayer is an orthopedic surgeon in Wallingford, Connecticut. He is affiliated with numerous hospitals in the region. Dr. Axtmayer serves as an Associate Professor at the MidState Medical Center Campus Department of Surgery, as a Clinical Instructor in Orthopaedics and Rehabilitation at Yale University School of Medicine, and as an Assistant Clinical Professor in the Yale University School of Medicine's Department of Orthopaedics and Rehabilitation.

Digipath, Inc. (DIGP), closed Tuesday's trading session at $0.26, up 1.34%, on 77,609 volume with 29 trades. The average volume for the last 60 days is 277,514 and the stock's 52-week low/high is $0.09/$0.355.

Ironclad Performance Wear Corp. (ICPW)

Stock News Now, Zacks, and SmallCapVoice reported earlier on Ironclad Performance Wear Corp. (ICPW), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Ironclad Performance Wear Corp. is a leader in high-performance task-specific work gloves. In 1998 it created the performance work glove category. The Company engineers and manufactures its products with a focus on innovation, design, advanced material science, and durability. Ironclad Performance Wear sells its products under the Ironclad brand.  The Company is headquartered in Farmers Branch, Texas.

Ironclad Performance Wear continues to make the most of its leadership position in the safety, construction, and industrial markets through the design, development and distribution of specialized task-specific gloves for varied industries. These industries include oil & gas extraction; automotive; and police, fire, first-responder and military.

Ironclad offers technical gloves designed for individual user groups. This includes carpenters, machinists, package handlers, plumbers, welders, roofers, oil and gas workers, mechanics, hunters, gardeners, and do-it-yourself users. Also, the Company offers long and short sleeved shirts; and performance jackets, pants, shorts, reflective and polo shirts, underwear, and tights. 

The Company’s gloves and apparel are available through industrial suppliers, hardware stores, home centers, lumber yards, and sporting goods retailers throughout the U.S. Moreover, they are available through authorized distributors in North America, Europe, Australia, and Asia.

This past January, Ironclad Performance Wear and Glenfir Corporation announced that they entered into a five-year exclusive distribution agreement to distribute Ironclad products in the territories of Central and South America. Glenfir is a division of Kapern Corporation, a South American multi-national business with interests in quarry exploration, survey engineering, heavy machinery, and industrial safety.

Also in January, Ironclad Performance Wear announced that it realigned and expanded its sales management team. The changes will further focus talented company sales teams to aggressively go after key markets and opportunities. The Company announced that Mr. Ron Broussard joined Ironclad as its new Senior Vice President Industrial Sales. Mr. Broussard is a long-time glove industry executive, most recently with the Ansell Corporation. In addition, Ironclad announced that Mr. Michael Fowler was promoted to Senior Vice President for Retail Sales.

Last week, Ironclad Performance Wear reported financial results for Q4 and fiscal year ended December 31, 2016. The Company reported Net Sales for Q4 of 2016 of $8.3 million. This represents a decrease of 1 percent from the Q4 total of $8.4 million for 2015. Gross Profit increased to $3.0 million, or 36 percent of Net Sales in Q4 of 2016, versus $2.8 million, or 34 percent of Net Sales in Q4 of 2015.

Income from Operations rose for Q4 to $0.36 million or 4 percent versus $0.26 million or 3 percent during the same period in 2015. Net Income for Q4 was $0.32 million, or $0.00 per share, versus $0.24 million, or $0.00 per share, in the same period the year prior. 

Ironclad Performance Wear Corp. (ICPW), closed Tuesday's trading session at $0.26, up 4.38%, on 55,000 volume with 3 trades. The average volume for the last 60 days is 64,543 and the stock's 52-week low/high is $0.2001/$0.295.

Mikros Systems Corp. (MKRS)

Wall Street Mover, Promotion Stock Secrets, Marketbeat, Fast Money Alerts, Actual Gains, AddictivePennyStocks, PennyStockRumors.net, PricelessPennyStocks, PennyStockLocks, StockBomb, StockLockandLoad, ResearchOTC, StockRockandRoll, and PennyStocks24 reported earlier on Mikros Systems Corp. (MKRS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Mikros Systems Corp. is a provider of advanced maintenance and monitoring solutions for mission-critical systems. The Company is an advanced technology enterprise that designs and manufactures specialized electronic systems for the Department of Defense. Its chief business is to pursue and obtain contracts from the Department of Homeland Security, the U.S. Navy, and other governmental authorities. The Company is headquartered in Princeton, New Jersey. Mikros Systems has its Manufacturing and Depot Center in Largo, Florida.

The Company has developed, delivered, and installed military-grade equipment to Federal customers for more than three decades. Mikros Systems’ capabilities include technology management, electronic systems engineering and integration, radar systems engineering, command, control, communications, computers and intelligence systems engineering, and communications engineering.

Mikros Systems produces advanced maintenance systems for the Navy. These include the ADEPT Maintenance Automation Workstation and the ADSSS Condition Based Maintenance system for the Littoral Combat Ship.  ADEPT systems are in use daily for performance optimization of advanced radar systems.  

The Company has required processes in place for the handling, accounting, storage and control of classified material. Mikros’ Lifecycle Support capability is centered on ensuring the systematic interactions between Integrated Logistics Support (ILS), Depot, and Field Support activities are integrated to attain the highest levels of system readiness.

Mikros Systems has purchased certain software products, intellectual property (IP) and related assets from VSE Corp. The main software programs purchased by Mikros are the Prognostics Framework (PF) and Diagnostic Profiler (DP) programs. The Diagnostic Profiler software is used around the world by many multinational companies for optimized maintenance of varied product lines.

Diagnostic Profiler is also used by the U.S. Air Force for depot test programs. Prognostics Framework is used by the U.S. Army for several missile defense systems. These software products provide Mikros Systems with the opportunity to service commercial customers and additional Department of Defense customers outside the Navy.

In September 2016, Mikros Systems announced that it received its first commercial full-rate production order for its manufacturing and depot center in Largo, Florida. This center established in 2009 to manufacture and provide sustainment and logistics support for the Mikros Systems Adaptive Diagnostic Electronic Portable Testset (ADEPT®) system for the U.S. Navy.

Last week, Mikros Systems announced that it received a three-year $11.5 million order from the U.S. Navy for engineering and technical support of its ADEPT maintenance workstation. The award is the second Delivery Order issued under Mikros' Indefinite Delivery Indefinite Quantity multi-year $35.1 million contract with the Naval Surface Warfare Center in Crane, Indiana.

Mikros Systems Corp. (MKRS), closed Tuesday's trading session at $0.37, even for the day, on 56,675 volume with 14 trades. The average volume for the last 60 days is 38,096 and the stock's 52-week low/high is $0.0667/$0.3899.

El Capitan Precious Metals, Inc. (ECPN)

SmallCapVoice, BullRally, CoolPennyStocks, HotOTC, MadPennyStocks, PennyInvest, PennyStockVille, StockEgg, and StockRich reported earlier on El Capitan Precious Metals, Inc. (ECPN), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

El Capitan Precious Metals, Inc. is a mining company whose shares trade on the OTC Markets’ OTCQB. The Company mainly engages in the mining of precious metals and other minerals. It principally holds interest in the El Capitan gold-silver property located close to Capitan, New Mexico, in Lincoln County. El Capitan Precious Metals’ chief asset is its wholly-owned subsidiary El Capitan, Ltd., an Arizona corporation. El Capitan Precious Metals is based in Scottsdale, Arizona.

The El Capitan, Ltd. subsidiary holds the 100 percent equity interest in the El Capitan property. The El Capitan deposit has been known as a potential iron ore resource for many decades. The El Capitan deposit has a near-surface, pervasive nature. All of this takes place above the regional water table. This provides the potential for a low mining cost and a long life operation. The Company’s primary goal is the sale of the El Capitan property.

El Capitan Precious Metals owns 3,840 acres of mining property in Lincoln County. This includes 80 acres of patented and 3,760 acres of leased property. These include 188 mining claims. The El Capitan property covers 354 Bureau of Land Management (BLM) lode claims and four patented claims.

The Company has enhanced its relationship with Logistica US by way of an agreement under which El Capitan will provide to Logistica concentrated ore to their specifications at the mine site. Logistica will transport, process, and refine the precious metals concentrates to sell to precious metals buyers. The agreement is in addition to and complements the earlier announced agreement for the sale of iron ore for use in construction.

Major advances in El Capitan’s precious metals recovery process have produced gold and platinum beads, which are 99 percent pure, from its ultra-fine concentrates. The new recovery process is the result of earlier collaborations and is replicable and scalable.

Last month, El Capitan Precious Metals announced that the AuraSource II machine that will process its concentrates for sale directly to refiners arrived at the pilot plan site. It was operational by the end of February 2017. The multi-million-dollar, proprietary technology of this device (imported from China) was specifically designed and calibrated for the final processing of El Capitan concentrates. It is uniquely suited for the recovery of precious metals from the El Capitan ore.

Recently, El Capitan Precious Metals announced that the U.S. Forest Service agreed to El Capitan’s use of Right of Way road access at its New Mexico mine site. The agreement represents El Capitan’s ability to overcome another obstacle on its path toward supporting its mining operations and revenue generation.

El Capitan Precious Metals, Inc. (ECPN), closed Tuesday's trading session at $0.08345, down 4.36%, on 786,574 volume with 39 trades. The average volume for the last 60 days is 396,794 and the stock's 52-week low/high is $0.0302/$2.35.

Bravada Gold Corp. (BGAVF)

Gold Investment Letter and Real Pennies reported earlier on Bravada Gold Corp. (BGAVF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Bravada Gold Corp. is a Nevada-focused exploration and development company.  Bravada has a large portfolio of high-quality properties. These encompass a range of development stages - from early-stage exploration to advanced-stage exploration and pre-development. Bravada Gold has its corporate office in Vancouver, British Columbia.

On January 19, 2017, Bravada Gold announced that the OTC Markets Group approved the Company’s common shares for listing on the OTCQB Marketplace as of that day. Subsequently, Bravada commenced trading on that exchange.

The Company explores for precious metals in well-established gold trends in one of the world's best gold jurisdictions. At present, five of Bravada Gold’s Nevada properties are being funded by partners. In total this includes earn-in work expenditures of up to $6.5 million and payments to Bravada Gold of up to +$3.0 million in cash and shares. Bravada retains residual working or royalty interests.

For this year, Bravada Gold says that mine permitting continues on its Shoshone Pediment project. Bravada holds a royalty on eventual barite production.

Regarding the North Lone Mountain and South Lone Mountain projects, plans have not been finalized for Bravada’s two claim groups. Nonetheless, Nevada Zinc continues to expand the footprint of zinc mineralization on its claims towards Bravada’s South Lone Mountain claims. Should Nevada Zinc complete the purchase of these claims, Bravada Gold will retain a royalty on base and precious metals.

Concerning its Wind Mountain project, Bravada’s plan is to drill-test for high-grade “Hishikari-type” gold/silver vein mineralization beneath the existing disseminated resource at Wind Mountain. Pertaining to the SF property, the Company plans to drill-test for high-grade “Carlin-type” gold mineralization at the SF property this year.

Last month, Bravada Gold announced that it closed the second tranche of its earlier reported non-brokered private placement by issuing 466,605 units at a price of $0.20 per unit for gross proceeds of $93,321.

Bravada Gold Corp. (BGAVF), closed Tuesday's trading session at $0.17, up 3.94%, on 20,022 volume with 3 trades. The average volume for the last 60 days is 17,278 and the stock's 52-week low/high is $0.055/$0.3136.

graphic

The QualityStocks
Company Corner

graphic
graphic

TapImmune, Inc. (NASDAQ: TPIV)

The QualityStocks Daily Newsletter would like to spotlight TapImmune, Inc. (TPIV). Today, TapImmune, Inc. closed trading at $4.81, up 4.11%, on 159,373 volume with 442 trades. The stock’s average daily volume over the past 60 days is 37,518, and its 52-week low/high is $3.32/$9.828.

TapImmune, Inc. today announced that its collaborators at the Mayo Clinic, recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on TapImmune's HER2/neu-targeted T-cell vaccine that will enroll women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS). If successful, TapImmune's vaccine may replace standard surgery and chemotherapy, and potentially could become part of a routine immunization schedule for preventing breast cancer in healthy women.

TapImmune, Inc. (TPIV) is leading the field of oncology with its next-generation T-cell vaccines and novel immunotherapy platforms. By fully leveraging the scope of its technology and through collaborative partnerships and license agreements, the company aims to maximize its value and growth potential.

Most cancer patients die from metastatic disease, which is when the cancer travels to other parts of the body that ultimately cannot be treated, instead of the primary tumor. TapImmune's immunotherapies overcome the deficiencies of earlier cancer vaccine approaches by targeting both tumors and metastatic diseases. The company's approach further differentiates itself by influencing the body's own immune system to fight the disease.

Two clinical stage T-cell vaccine candidates are currently being advanced in multiple Phase II and Phase Ib/IIa clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from the FDA Fast Track and Orphan Disease Designation. The U.S. market alone is very large for these cancers, with a combined 290,000 new patients estimated to be diagnosed each year. Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca are among the collaborators in these trials, and the U.S. Department of Defense has provided significant non-dilutive funding as well.

The company's off-the-shelf vaccines have been proven to boost patients' immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells, and they are designed to treat a wide patient population across varied therapeutic areas of cancer. These vaccines have the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics.

PolyStart is TapImmune's unique DNA-based antigen expression system that helps the body recognize and kill target cells. It is a novel vaccine technology platform that creates a four-fold or greater increase in presentation of any antigen, which gives it unlimited application in oncology and infectious disease. The PolyStart platform further solidifies the company as a leader in the development of next-generation vaccines for cancer as it will be able to use this technology for its own vaccine candidates as well as generate additional value for the platform by licensing it to third parties.

The company plans to first build value through advancing candidates that treat women's cancers, while continuously developing its unique pipeline. As part of its long-term vision, the company is also developing proprietary technologies that can enhance the potency of DNA-based immunotherapies against other types of cancer and infectious disease. Other goals include discovering, acquiring and developing additional technologies that modulate antigen presentation and driving incremental value by monetizing proprietary protein expression systems through business partnerships. Disclaimer

TapImmune, Inc. Company Blog

TapImmune, Inc. News:

TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer

TapImmune to Host Inaugural Quarterly Business Update Conference Call and Webcast

TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review

eXp World Holdings, Inc. (EXPI)

The QualityStocks Daily Newsletter would like to spotlight eXp World Holdings, Inc. (EXPI). Today, eXp World Holdings, Inc. closed trading at $3.788, up 1.01%, on 16,360 volume with 23 trades. The stock’s average daily volume over the past 60 days is 12,238, and its 52-week low/high is $0.841/$5.84.

eXp World Holdings, Inc. (EXPI) is the holding company for a number of businesses, most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage™. eXp Realty is a full-service real estate brokerage offering 24/7 access to a suite of collaborative tools, training features and socialization channels designed to meet the unique needs of real estate brokers and agents. By creating a fully-immersive, cloud office environment for real estate professionals, eXp effectively reduces agents' overhead, increases their profits and provides greater service value to consumers.

Through eXp Realty's innovative platform, agents and brokers are afforded the opportunity to earn equity in exchange for production and contributions to company growth. Additionally, eXp features an aggressive revenue sharing program that pays agents a percentage of the gross commission income earned by fellow professionals they recruit into the company. The result is a shared ownership community featuring a synergistic and collaborative group of forward-thinking, entrepreneurial professionals. With the emergence of the internet as the most powerful property marketing and advertising medium, eXp's internet and cloud technologies have helped thousands of consumers find, buy or sell homes without the need for a brick and mortar real estate office.

Since its launch in October 2009, eXp Realty has experienced rapid growth, with brokerage service now offered in 35 U.S. states and Alberta, Canada. In February 2016, the company officially welcomed its 1,000th real estate professional into its family of agent-owners, up from just 467 agents at the end of 2014. Following this achievement, the Agent-Owned Cloud Brokerage claimed a spot among the top 50 real estate brokerages in the United States based on agent count, according to data from RISMEDIA's 2015 PowerBroker 500 Report.

Similarly, eXp Realty generated record financial results during 2015. Following the launch of two new initiatives – including an online lead generation program and a stock compensation plan – the company achieved a 71 percent year-over-year increase in net revenues, recording $22.87 million for the year. As it continues to expand its footprint across North America, eXp Realty will look to leverage its unique agent-owned business model to continue attracting driven, entrepreneurial agents and real estate industry leaders while promoting sustainable financial growth. Disclaimer

eXp World Holdings, Inc. Company Blog

eXp World Holdings, Inc. News:

eXp World Holdings to Present at Annual ROTH Conference

Super Bowl Quarterback Vince Ferragamo Joins eXp Realty

eXp World Holdings, Inc. to Host Corporate Update Webinar on February 23rd

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.73, up 4.29%, on 127,293 volume with 66 trades. The stock’s average daily volume over the past 60 days is 53,803 and its 52-week low/high is $0.05/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

NetworkNewsWire Releases Exclusive Audio Interview with ORHub, Inc. (ORHB)

ORhub, Inc. (ORHB) Engages NetworkNewsWire for Corporate Communications Solutions

ORHub, Inc. (ORHB) Expands Operations at Nation's Second Largest Non-Profit Hospital System

India Globalization Capital, Inc. (IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.325, up 4.17%, on 114,547 volume with 285 trades. The stock’s average daily volume over the past 60 days is 170,014, and its 52-week low/high is $0.19/$0.83.

India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer

India Globalization Capital, Inc. Company Blog

India Globalization Capital, Inc. News:

IGC Announces Third Quarter Financial Results

India Globalization Capital Announces the Extension of Warrants’ Expiry Date and Inducement Grant to its CFO

IGC Update on Iron Ore Subsidiary

GreenStone Healthcare Corp. (GRST)

The QualityStocks Daily Newsletter would like to spotlight GreenStone Healthcare Corp. (GRST). Today, GreenStone Healthcare Corp. closed trading at $0.0398, up 17.06%, on 2,600 volume with 2 trades. The stock’s average daily volume over the past 60 days is 65,263, and its 52-week low/high is $0.015/$0.083.

GreenStone Healthcare Corp. (GRST), through its subsidiaries, offers addiction and mental health rehabilitation treatments for residents, including out-patient counseling, coaching, intervention, psychological assessment, and other related services. The company recently sold its Canadian addiction treatment operations and acquired a U.S. based treatment center in Delray Beach, Florida, a major U.S. center for drug treatment programs located between Palm Beach and Miami. The company sought to expand into the U.S., where it could revolutionize treatment in that country with the skills it acquired in Canada. The company, through a subsidiary, will own and lease their assets in Canada, offering a stable secondary cash flow. Their newly acquired U.S. treatment center will be operated through a Florida limited liability company named Seastone Delray Healthcare LLC.

More than two thirds of families have been touched by a family member's addiction to alcohol, drugs, sex, and/or gambling. The addiction treatment market in the U.S. is estimated at over $35 billion annually, with a greater need than there are facilities. In addition, the GreeneStone approach differentiates itself in a number of ways:

  • Residents are treated holistically, taking into consideration all factors that can feed addiction, rather than the isolated treatment of addiction alone. Upon admission, all residents are fully assessed by professionals of a multidisciplinary team to develop an overall holistic treatment plan. An assembled team of best-in-class experts, including psychiatrists, physicians, nurses, and clinicians, manage and support residents who have co-occurring disorders such as depression, anxiety, and trauma.
  • Support is available both before and after resident treatment. Families can receive intervention support prior to admission, an often critical time for families and patients. Follow-up treatment support is available, to ensure progress and minimize the incidence of relapse. Families and others that are integral to the recovery are encouraged to participate in counseling and education sessions for continued success after in-patient treatment.

In addition to his experience with GreeneStone Healthcare, company president Shawn Leon has more than 25 years of experience managing public and private development-stage companies for various industries. He has provided financing and capital markets oversight for a number of these ventures, many of which have involved negotiations for mergers and acquisitions. Disclaimer

GreenStone Healthcare Corp. Company Blog

GreenStone Healthcare Corp. News:

GreeneStone Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida

GreeneStone Signs Definitive Agreement to Acquire Seastone of Delray, a Florida Limited Liability Company

GreeneStone Signs LOI to Acquire Aurora Recovery

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

InvestorPlace
(LGYV) +1,328%

2.

Small Cap Firm
(FLCR) +70.00%

3.

StockMarketWatch
(DRWI) +65.22%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251